IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer
IL-33 is a member of the IL-1 family of cytokines, and no study has been performed to address its direct anti-tumor effect. This study is designed to investigate whether IL-33 has any direct effect on pancreatic cancer. Clonogenic survival assay, immunohistochemistry, TUNEL staining, proliferation,...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2017-02, Vol.34 (2), p.23-23, Article 23 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 23 |
|---|---|
| container_issue | 2 |
| container_start_page | 23 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 34 |
| creator | Fang, Yujiang Zhao, Lei Xiao, Huaping Cook, Kathryn M. Bai, Qian Herrick, Elizabeth J. Chen, Xuhui Qin, Chenglu Zhu, Ziwen Wakefield, Mark R. Nicholl, Michael B. |
| description | IL-33 is a member of the IL-1 family of cytokines, and no study has been performed to address its direct anti-tumor effect. This study is designed to investigate whether IL-33 has any direct effect on pancreatic cancer. Clonogenic survival assay, immunohistochemistry, TUNEL staining, proliferation, caspase-3 activity kits and RT-PCR were used to evaluate the effects of IL-33 on cell survival, proliferation and apoptosis of a pancreatic cancer cell line, MIA PaCa-2. We found that the percentage of colonies of MIA PaCa-2 cells, PCNA+ cells and the OD value of cancer cells were all decreased in the presence of IL-33. TUNEL+ cells and the relative caspase-3 activity in cancer cells were increased in the presence of IL-33. We further found that its anti-proliferative effect on cancer cells correlated with downregulation of pro-proliferative molecules cdk2 and cdk4 and upregulation of anti-proliferative molecules p15, p21 and p53. Its pro-apoptotic effect correlated with downregulation of anti-apoptotic molecule FLIP and upregulation of pro-apoptotic molecule TRAIL. These results suggest that IL-33 presents significant anti-tumor effects by inhibition of proliferation and induction of apoptosis of MIA PaCa-2 pancreatic cancer cells. Thus, strength of IL-33/ST2 signal pathway might be a promising way to treat pancreatic cancer. |
| doi_str_mv | 10.1007/s12032-016-0880-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1856588878</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4294011291</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-4b7802ee001773acc457b40de767927ac504d292498c12070ea875de6521af63</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlZ_gBcJePESnSSbjz2W4kehoocevIU0Oystbbcmuwf_vSlbRQQhkIF55k3mIeSSwy0HMHeJC5CCAdcMrAUmj8iQK1UyLvnbca6lMgyUhgE5S2kFILgS5SkZCAvKaglDIqczJiX1oU3U50PrBmnb0OfpmL76iWeC7vw2RPTtMtCQS4zn5KT264QXh3tE5g_388kTm708TifjGQuFtC0rFsaCQATgxkgfQqHMooAKjTalMD4oKCpRiqK0IS9iAL01qkKtBPe1liNy08fuYvPRYWrdZpkCrtd-i02XHLdKK2utsRm9_oOumi5u8-f2lNKltsJkivdUiE1KEWu3i8uNj5-Og9sLdb1Ql4W6vVAn88zVIblbbLD6mfg2mAHRAym3tu8Yfz39b-oXUqt6zA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1855696827</pqid></control><display><type>article</type><title>IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Fang, Yujiang ; Zhao, Lei ; Xiao, Huaping ; Cook, Kathryn M. ; Bai, Qian ; Herrick, Elizabeth J. ; Chen, Xuhui ; Qin, Chenglu ; Zhu, Ziwen ; Wakefield, Mark R. ; Nicholl, Michael B.</creator><creatorcontrib>Fang, Yujiang ; Zhao, Lei ; Xiao, Huaping ; Cook, Kathryn M. ; Bai, Qian ; Herrick, Elizabeth J. ; Chen, Xuhui ; Qin, Chenglu ; Zhu, Ziwen ; Wakefield, Mark R. ; Nicholl, Michael B.</creatorcontrib><description>IL-33 is a member of the IL-1 family of cytokines, and no study has been performed to address its direct anti-tumor effect. This study is designed to investigate whether IL-33 has any direct effect on pancreatic cancer. Clonogenic survival assay, immunohistochemistry, TUNEL staining, proliferation, caspase-3 activity kits and RT-PCR were used to evaluate the effects of IL-33 on cell survival, proliferation and apoptosis of a pancreatic cancer cell line, MIA PaCa-2. We found that the percentage of colonies of MIA PaCa-2 cells, PCNA+ cells and the OD value of cancer cells were all decreased in the presence of IL-33. TUNEL+ cells and the relative caspase-3 activity in cancer cells were increased in the presence of IL-33. We further found that its anti-proliferative effect on cancer cells correlated with downregulation of pro-proliferative molecules cdk2 and cdk4 and upregulation of anti-proliferative molecules p15, p21 and p53. Its pro-apoptotic effect correlated with downregulation of anti-apoptotic molecule FLIP and upregulation of pro-apoptotic molecule TRAIL. These results suggest that IL-33 presents significant anti-tumor effects by inhibition of proliferation and induction of apoptosis of MIA PaCa-2 pancreatic cancer cells. Thus, strength of IL-33/ST2 signal pathway might be a promising way to treat pancreatic cancer.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-016-0880-3</identifier><identifier>PMID: 28058630</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Apoptosis - drug effects ; Cell Growth Processes - drug effects ; Cell Line, Tumor ; Hematology ; Humans ; Interleukin-1 Receptor-Like 1 Protein - biosynthesis ; Interleukin-33 - pharmacology ; Internal Medicine ; Medicine ; Medicine & Public Health ; Oncology ; Original Paper ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - pathology ; Pathology</subject><ispartof>Medical oncology (Northwood, London, England), 2017-02, Vol.34 (2), p.23-23, Article 23</ispartof><rights>Springer Science+Business Media New York 2017</rights><rights>Medical Oncology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-4b7802ee001773acc457b40de767927ac504d292498c12070ea875de6521af63</citedby><cites>FETCH-LOGICAL-c438t-4b7802ee001773acc457b40de767927ac504d292498c12070ea875de6521af63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-016-0880-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-016-0880-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28058630$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fang, Yujiang</creatorcontrib><creatorcontrib>Zhao, Lei</creatorcontrib><creatorcontrib>Xiao, Huaping</creatorcontrib><creatorcontrib>Cook, Kathryn M.</creatorcontrib><creatorcontrib>Bai, Qian</creatorcontrib><creatorcontrib>Herrick, Elizabeth J.</creatorcontrib><creatorcontrib>Chen, Xuhui</creatorcontrib><creatorcontrib>Qin, Chenglu</creatorcontrib><creatorcontrib>Zhu, Ziwen</creatorcontrib><creatorcontrib>Wakefield, Mark R.</creatorcontrib><creatorcontrib>Nicholl, Michael B.</creatorcontrib><title>IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>IL-33 is a member of the IL-1 family of cytokines, and no study has been performed to address its direct anti-tumor effect. This study is designed to investigate whether IL-33 has any direct effect on pancreatic cancer. Clonogenic survival assay, immunohistochemistry, TUNEL staining, proliferation, caspase-3 activity kits and RT-PCR were used to evaluate the effects of IL-33 on cell survival, proliferation and apoptosis of a pancreatic cancer cell line, MIA PaCa-2. We found that the percentage of colonies of MIA PaCa-2 cells, PCNA+ cells and the OD value of cancer cells were all decreased in the presence of IL-33. TUNEL+ cells and the relative caspase-3 activity in cancer cells were increased in the presence of IL-33. We further found that its anti-proliferative effect on cancer cells correlated with downregulation of pro-proliferative molecules cdk2 and cdk4 and upregulation of anti-proliferative molecules p15, p21 and p53. Its pro-apoptotic effect correlated with downregulation of anti-apoptotic molecule FLIP and upregulation of pro-apoptotic molecule TRAIL. These results suggest that IL-33 presents significant anti-tumor effects by inhibition of proliferation and induction of apoptosis of MIA PaCa-2 pancreatic cancer cells. Thus, strength of IL-33/ST2 signal pathway might be a promising way to treat pancreatic cancer.</description><subject>Apoptosis - drug effects</subject><subject>Cell Growth Processes - drug effects</subject><subject>Cell Line, Tumor</subject><subject>Hematology</subject><subject>Humans</subject><subject>Interleukin-1 Receptor-Like 1 Protein - biosynthesis</subject><subject>Interleukin-33 - pharmacology</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pathology</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE1LAzEQhoMotlZ_gBcJePESnSSbjz2W4kehoocevIU0Oystbbcmuwf_vSlbRQQhkIF55k3mIeSSwy0HMHeJC5CCAdcMrAUmj8iQK1UyLvnbca6lMgyUhgE5S2kFILgS5SkZCAvKaglDIqczJiX1oU3U50PrBmnb0OfpmL76iWeC7vw2RPTtMtCQS4zn5KT264QXh3tE5g_388kTm708TifjGQuFtC0rFsaCQATgxkgfQqHMooAKjTalMD4oKCpRiqK0IS9iAL01qkKtBPe1liNy08fuYvPRYWrdZpkCrtd-i02XHLdKK2utsRm9_oOumi5u8-f2lNKltsJkivdUiE1KEWu3i8uNj5-Og9sLdb1Ql4W6vVAn88zVIblbbLD6mfg2mAHRAym3tu8Yfz39b-oXUqt6zA</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Fang, Yujiang</creator><creator>Zhao, Lei</creator><creator>Xiao, Huaping</creator><creator>Cook, Kathryn M.</creator><creator>Bai, Qian</creator><creator>Herrick, Elizabeth J.</creator><creator>Chen, Xuhui</creator><creator>Qin, Chenglu</creator><creator>Zhu, Ziwen</creator><creator>Wakefield, Mark R.</creator><creator>Nicholl, Michael B.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170201</creationdate><title>IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer</title><author>Fang, Yujiang ; Zhao, Lei ; Xiao, Huaping ; Cook, Kathryn M. ; Bai, Qian ; Herrick, Elizabeth J. ; Chen, Xuhui ; Qin, Chenglu ; Zhu, Ziwen ; Wakefield, Mark R. ; Nicholl, Michael B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-4b7802ee001773acc457b40de767927ac504d292498c12070ea875de6521af63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Apoptosis - drug effects</topic><topic>Cell Growth Processes - drug effects</topic><topic>Cell Line, Tumor</topic><topic>Hematology</topic><topic>Humans</topic><topic>Interleukin-1 Receptor-Like 1 Protein - biosynthesis</topic><topic>Interleukin-33 - pharmacology</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fang, Yujiang</creatorcontrib><creatorcontrib>Zhao, Lei</creatorcontrib><creatorcontrib>Xiao, Huaping</creatorcontrib><creatorcontrib>Cook, Kathryn M.</creatorcontrib><creatorcontrib>Bai, Qian</creatorcontrib><creatorcontrib>Herrick, Elizabeth J.</creatorcontrib><creatorcontrib>Chen, Xuhui</creatorcontrib><creatorcontrib>Qin, Chenglu</creatorcontrib><creatorcontrib>Zhu, Ziwen</creatorcontrib><creatorcontrib>Wakefield, Mark R.</creatorcontrib><creatorcontrib>Nicholl, Michael B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fang, Yujiang</au><au>Zhao, Lei</au><au>Xiao, Huaping</au><au>Cook, Kathryn M.</au><au>Bai, Qian</au><au>Herrick, Elizabeth J.</au><au>Chen, Xuhui</au><au>Qin, Chenglu</au><au>Zhu, Ziwen</au><au>Wakefield, Mark R.</au><au>Nicholl, Michael B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>34</volume><issue>2</issue><spage>23</spage><epage>23</epage><pages>23-23</pages><artnum>23</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>IL-33 is a member of the IL-1 family of cytokines, and no study has been performed to address its direct anti-tumor effect. This study is designed to investigate whether IL-33 has any direct effect on pancreatic cancer. Clonogenic survival assay, immunohistochemistry, TUNEL staining, proliferation, caspase-3 activity kits and RT-PCR were used to evaluate the effects of IL-33 on cell survival, proliferation and apoptosis of a pancreatic cancer cell line, MIA PaCa-2. We found that the percentage of colonies of MIA PaCa-2 cells, PCNA+ cells and the OD value of cancer cells were all decreased in the presence of IL-33. TUNEL+ cells and the relative caspase-3 activity in cancer cells were increased in the presence of IL-33. We further found that its anti-proliferative effect on cancer cells correlated with downregulation of pro-proliferative molecules cdk2 and cdk4 and upregulation of anti-proliferative molecules p15, p21 and p53. Its pro-apoptotic effect correlated with downregulation of anti-apoptotic molecule FLIP and upregulation of pro-apoptotic molecule TRAIL. These results suggest that IL-33 presents significant anti-tumor effects by inhibition of proliferation and induction of apoptosis of MIA PaCa-2 pancreatic cancer cells. Thus, strength of IL-33/ST2 signal pathway might be a promising way to treat pancreatic cancer.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28058630</pmid><doi>10.1007/s12032-016-0880-3</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2017-02, Vol.34 (2), p.23-23, Article 23 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1856588878 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Apoptosis - drug effects Cell Growth Processes - drug effects Cell Line, Tumor Hematology Humans Interleukin-1 Receptor-Like 1 Protein - biosynthesis Interleukin-33 - pharmacology Internal Medicine Medicine Medicine & Public Health Oncology Original Paper Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Pathology |
| title | IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T03%3A04%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IL-33%20acts%20as%20a%20foe%20to%20MIA%20PaCa-2%20pancreatic%20cancer&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Fang,%20Yujiang&rft.date=2017-02-01&rft.volume=34&rft.issue=2&rft.spage=23&rft.epage=23&rft.pages=23-23&rft.artnum=23&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-016-0880-3&rft_dat=%3Cproquest_cross%3E4294011291%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1855696827&rft_id=info:pmid/28058630&rfr_iscdi=true |